A Comprehensive Review of <i>HLA</i> and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine
Human leukocyte antigen (<i>HLA</i>) encoded by the <i>HLA</i> gene is an important modulator for immune responses and drug hypersensitivity reactions as well. Genetic polymorphisms of <i>HLA</i> vary widely at population level and are responsible for developing s...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a73aaaba377c4b0ebe02f1345961e5ca |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Human leukocyte antigen (<i>HLA</i>) encoded by the <i>HLA</i> gene is an important modulator for immune responses and drug hypersensitivity reactions as well. Genetic polymorphisms of <i>HLA</i> vary widely at population level and are responsible for developing severe cutaneous adverse drug reactions (SCARs) such as Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), maculopapular exanthema (MPE). The associations of different <i>HLA</i> alleles with the risk of drug induced SJS/TEN, DRESS and MPE are strongly supportive for clinical considerations. Prescribing guidelines generated by different national and international working groups for translation of <i>HLA</i> pharmacogenetics into clinical practice are underway and functional in many countries, including Thailand. Cutting edge genomic technologies may accelerate wider adoption of <i>HLA</i> screening in routine clinical settings. There are great opportunities and several challenges as well for effective implementation of <i>HLA</i> genotyping globally in routine clinical practice for the prevention of drug induced SCARs substantially, enforcing precision medicine initiatives. |
|---|